Q1 2026 · 13F-HR
Kalehua Capital Management LLCholdings as filed
Filed 2026-05-15 · accession 0002106181-26-000004
$118.6M
Reported value
23
Positions
2026-03-31
Period end
The Brief · Kalehua Capital Management LLC · Q1 2026
AI · grounded in 13F
Kalehua Capital Management LLC established a new position in Veradermics Inc MANE valued at $6.49M. The fund also opened new stakes in ACLARIS THERAPEUTICS INC ACRS for $5.01M and Damora Therapeutics Inc DMRA for $3.6M. These additions coincided with the complete exit of positions in Allogene Therapeutics Inc ALLO and Oric Pharmaceuticals Inc ORIC.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 98420X202 | XFOR | X4 Pharmaceuticals Inc | $15.4M | 13.0% | 3,722,840 | Common | SOLE |
| 02072L565 | BOXX | Alpha Architect 1-3 Month Box ETF | $13.8M | 11.6% | 118,422 | Common | SOLE |
| 86889P208 | SRZN | Surrozen Inc | $11.2M | 9.46% | 385,178 | Common | SOLE |
| 75943R102 | RLAY | Relay Therapeutics Inc | $9.0M | 7.56% | 901,457 | Common | SOLE |
| 829401108 | SION | Sionna Therapeutics Inc | $7.9M | 6.66% | 197,072 | Common | SOLE |
| 922967104 | MANE | Veradermics Inc | $6.5M | 5.48% | 102,879 | Common | SOLE |
| 687604108 | ORKA | Oruka Therapeutics Inc | $5.8M | 4.90% | 118,524 | Common | SOLE |
| N69605108 | PHVS | Pharvaris NV | $5.6M | 4.73% | 198,772 | Common | SOLE |
| 00461U105 | ACRS | ACLARIS THERAPEUTICS INC | $5.0M | 4.23% | 1,337,556 | Common | SOLE |
| 81734D104 | SEPN | Septerna Inc | $4.7M | 3.94% | 194,544 | Common | SOLE |
| 20451W101 | CMPS | Compass Pathways PLC | $4.5M | 3.82% | 819,692 | Common | SOLE |
| 45719W205 | IKT | Inhibikase Therapeutics Inc | $4.5M | 3.79% | 2,672,608 | Common | SOLE |
| 04746L203 | LONA | LeonaBio Inc | $4.0M | 3.41% | 393,701 | Common | SOLE |
| 36322Q206 | DMRA | Damora Therapeutics Inc | $3.6M | 3.04% | 139,000 | Common | SOLE |
| N90064101 | QURE | Uniqure NV | $3.5M | 2.92% | 211,702 | Common | SOLE |
| 61559X104 | MLTX | MoonLake Immunotherapeutics | $3.3M | 2.76% | 175,734 | Common | SOLE |
| 90240B106 | TYRA | Tyra Biosciences Inc | $2.9M | 2.40% | 74,465 | Common | SOLE |
| 38341P102 | GOSS | Gossamer Bio Inc | $2.5M | 2.07% | 7,471,840 | Common | SOLE |
| 87990A106 | TNYA | Tenaya Therapeutics Inc | $1.4M | 1.17% | 2,000,000 | Common | SOLE |
| 713317105 | PEPG | PepGen Inc | $1.3M | 1.09% | 729,961 | Common | SOLE |
| 45783C200 | TIL | Instil Bio Inc | $1.2M | 0.97% | 139,849 | Common | SOLE |
| 482929106 | KLRS | Kalaris Therapeutics Inc | $782,325 | 0.66% | 135,585 | Common | SOLE |
| 25253X207 | DMAC | DiaMedica Therapeutics Inc | $423,044 | 0.36% | 62,488 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.